CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data

CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data is organized by Physicians' Education Resource, LLC (PER).

Release Date: June 23, 2022
Expiration Date: June 23, 2023

Activity Overview:
This online, on-demand virtual symposium brings together renowned experts to discuss the use of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory multiple myeloma (RRMM). CAR T-cell therapy has proven to be an effective therapy for patients with multiply relapsed multiple myeloma (MM), yielding deep and durable responses. In this educational program, these experts discuss updates of clinical trials evaluating CAR T-cell therapies in patients with MM, expert perspectives on the current role of CAR T-cell therapies in MM, and strategies to identify patients eligible for CAR T-cell therapy and mitigate and manage toxicity related to CAR T-cell therapy.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Discuss the mechanistic rationale underlying the role of CAR T cells in the treatment of multiple myeloma (MM)
• Determine the efficacy and safety results from recent trials assessing CAR T-cell therapies in patients with MM
• Place these results in the context of evolving paradigms in MM management
• Plan strategies to monitor and mitigate treatment-associated toxicities in patients who receive CAR T-cell therapy

Additional details will be posted as soon as information is available.